Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

被引:62
作者
Egan, MA
Chong, SY
Megati, S
Montefiori, DC
Rose, NF
Boyer, JD
Sidhu, MK
Quiroz, J
Rosati, M
Schadeck, EB
Pavlakis, GN
Weiner, DB
Rose, JK
Israel, ZR
Udem, SA
Eldridge, JH
机构
[1] Wyeth Vaccines Res, Dept Vaccine Discovery, Pearl River, NY 10965 USA
[2] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[3] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[5] Wyeth Biometr Res, Pearl River, NY 10965 USA
[6] NCI, Human Retrovirus Sect, Basic Res Lab, Frederick, MD 21702 USA
关键词
D O I
10.1089/aid.2005.21.629
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Of the various approaches being developed as prophylactic HIV vaccines, those based on a heterologous; plasmid DNA prime, live vector boost vaccination regimen appear especially promising in the nonhuman primate/simian-human immunodeficiency virus (SHIV) challenge model. In this study, we sought to determine whether a series of intramuscular priming immunizations with a plasmid DNA vaccine expressing SIVgag p39, in combination with plasmid expressed rhesus IL-12, could effectively enhance the immunogenicity and postchallenge efficacy of two intranasal doses of recombinant vesicular stomatitis virus (rVSV)-based vectors expressing HIV-1 env 89.6P gp160 and SIVmac239 gag p55 in rhesus macaques. In macaques receiving the combination plasmid DNA prime, rVSV boost vaccination regimen we observed significantly increased SIVgag-specific cell-mediated and humoral immune responses and significantly lower viral loads postintravenous SHIV89.6P challenge relative to macaques receiving only the rVSV vectored immunizations. In addition, the plasmid DNA prime, rVSV boost vaccination regimen also tended to increase the preservation of peripheral blood CD4(+) cells and reduce the morbidity and mortality associated with SHIV89.6P infection. An analysis of immune correlates of protection after SHIV89.61? challenge revealed that the prechallenge SHIV-specific IFN-gamma ELISpot response elicited by vaccination and the ability of the host to mount a virus-specific neutralizing antibody response postchallenge correlated with postchallenge clinical outcome. The correlation between vaccine-elicited cell-mediated immune responses and an improved clinical outcome after SHIV challenge provides strong justification for the continued development of a cytokine-enhanced plasmid DNA prime, rVSV vector boost immunization regimen for the prevention of HIV infection.
引用
收藏
页码:629 / 643
页数:15
相关论文
共 68 条
[1]   Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine [J].
Amara, RR ;
Smith, JM ;
Staprans, SI ;
Montefiori, DC ;
Villinger, F ;
Altman, JD ;
O'Neil, SP ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McNicholl, JM ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (12) :6138-6146
[2]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[3]   Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines [J].
Amara, RR ;
Villinger, F ;
Staprans, SI ;
Altman, JD ;
Montefiori, DC ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7625-7631
[4]   Immunization of animals: from DNA to the dinner plate [J].
Babiuk, LA ;
van Drunen Littel-van den Hurk, S ;
Babiuk, SL .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1999, 72 (1-2) :189-202
[5]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[6]   Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers [J].
Belshe, RB ;
Stevens, C ;
Gorse, GJ ;
Buchbinder, S ;
Weinhold, K ;
Sheppard, H ;
Stablein, D ;
Self, S ;
McNamara, J ;
Frey, S ;
Flores, J ;
Excler, JL ;
Klein, M ;
El Habib, R ;
Duliege, AM ;
Harro, C ;
Corey, L ;
Keefer, M ;
Mulligan, M ;
Wright, P ;
Celum, C ;
Judson, F ;
Mayer, K ;
McKirnan, D ;
Marmor, M ;
Woody, G .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (09) :1343-1352
[7]   Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines [J].
Boyer, JD ;
Cohen, AD ;
Vogt, S ;
Schumann, K ;
Nath, B ;
Ahn, L ;
Lacy, K ;
Bagarazzi, ML ;
Higgins, TJ ;
Baine, Y ;
Ciccarelli, RB ;
Ginsberg, RS ;
MacGregor, RR ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :476-483
[8]   Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids [J].
Boyer, JD ;
Cohen, AD ;
Ugen, KE ;
Edgeworth, RL ;
Bennett, M ;
Shah, A ;
Schumann, K ;
Nath, B ;
Javadian, A ;
Bagarazzi, ML ;
Kim, J ;
Weiner, DB .
AIDS, 2000, 14 (11) :1515-1522
[9]   Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice [J].
Bruce, CB ;
Akrigg, A ;
Sharpe, SA ;
Hanke, T ;
Wilkinson, GWG ;
Cranage, MP .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2621-2628
[10]   Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].
Casimiro, DR ;
Chen, L ;
Fu, TM ;
Evans, RK ;
Caulfield, MJ ;
Davies, ME ;
Tang, A ;
Chen, MC ;
Huang, LY ;
Harris, V ;
Freed, DC ;
Wilson, KA ;
Dubey, S ;
Zhu, DM ;
Nawrocki, D ;
Mach, H ;
Troutman, R ;
Isopi, L ;
Williams, D ;
Hurni, W ;
Xu, Z ;
Smith, JG ;
Wang, S ;
Liu, X ;
Guan, LM ;
Long, R ;
Trigona, W ;
Heidecker, GJ ;
Perry, HC ;
Persaud, N ;
Toner, TJ ;
Su, Q ;
Liang, XP ;
Youil, R ;
Chastain, M ;
Bell, AJ ;
Volkin, DB ;
Emini, EA ;
Shiver, JW .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313